Zydus MD On Quest For Novel ADCs, Antibodies Amid Shifting Modalities

Zydus is developing a novel ADC, one of the most challenging but rewarding treatment modalities today as others in the class like Kadcyla and Enhertu prove. The Indian firm's managing director spoke to Scrip about R&D efforts, recent policy moves and gains from making the world’s first approved recombinant plasmid DNA vaccine.